Dallas Cowboys and Green Bay Packers played out a rare match tie in overtime at AT&T Stadium. By News Agencies Share Save Brandon Aubrey and Brandon McManus traded short field goals in overtime, and the highly anticipated return of Micah Parsons to Dallas ended with the Cowboys and Green Bay Packers in a 40-40 tie in the National Football League (NFL). Star quarterbacks Dak Prescott of Dallas and Green Bay’s Jordan Love had three touchdown passes apiece in regulation on Sunday night, which included seven consecutive lead-changing touchdowns before McManus’ tying 53-yard field goal as time expired. McManus kicked a 34-yarder as the clock hit 00:00 in overtime, just after Love’s pass into the back of the end zone fell incomplete with just a second remaining. What started as the hyped return of one of the game’s elite pass rushers, exactly a month after the Cowboys (1-2-1) traded Parsons to the Packers (2-1-1), ended up as the second dramatic duel of quarterbacks in as many home games for Dallas. The Cowboys beat the Giants 40-37 in overtime two weeks earlier when Russell Wilson was starting for New York. Sunday’s fixture was the second-highest scoring tie in NFL history – behind the Raiders’ 43-43 draw with the Boston Patriots in the American Football League (AFL) in 1964 – and was the first for Dallas since 1969. The Packers last tied in 2018. Follow Al Jazeera English:...

The US largely imports pharmaceutical products from India and European countries, including Ireland, Switzerland and Germany. By Sarah Shamim Share Save United States President Donald Trump said on Thursday that he will impose a 100 percent import tax on pharmaceutical drugs. He also announced new tariffs on other products. Here’s what we know, and what it all means. In a post on his Truth Social platform, Trump wrote that starting on October 1, the US will impose a 100 percent tariff on any branded or patented pharmaceutical product. The 100 percent tariff means prices of imported pharmaceutical products will double for US importers and consumers. However, Trump said an exception would be made for any company which “IS BUILDING their Pharmaceutical Manufacturing Plant in America”. He explained that “is building” refers to “‘breaking ground’ and/or ‘under construction'”. Trump did not specify whether the new tariffs he announced would be applied on top of the national tariffs he has previously imposed on various US trading partners. Pharmaceutical products, including packaged medicaments; vaccines, toxins and cultures; and hormones, made up about 5.6 percent of total US imports in 2023, worth about $158bn, according to the Observatory of Economic Complexity (OEC). During that year, the US imported $86.4bn worth of packaged medicaments. About 14.2 percent, or $12.3bn worth, of packaged medicaments came from Ireland; 14 percent, or $12.1bn worth, came from Switzerland; 13.4 percent ($11.6bn) from Germany; and 10.6 percent, or $9.2bn worth, came from India. Other countries from which the US imported these products include Italy, Denmark and the United Kingdom. In 2023, the US imported $65.1bn worth of vaccines, blood, antisera, toxins and cultures. Out of this, 23.2 percent, or $15.1bn worth, came from Ireland and 20.9 percent, or $13.6bn worth, from Germany. Pharmaceutical companies across Asia and Europe saw a drop in their share prices following Trump’s announcement. Swiss companies Lonza, Novartis and Roche were down about 1.2 percent in early trading on Friday. Shares in German drugmakers Merck and Bayer also fell by 1.1 percent and 1.5 percent, respectively. Japan’s Sumitomo Pharma closed 3.5 percent lower, while Otsuka Holdings fell 2.9 percent and Daiichi Sankyo dropped 2 percent. Not all pharma groups took a hit, however. Takeda Pharmaceutical edged down just 0.1 percent, while Shionogi, instead of falling, rose 1 percent. Meanwhile, in India, the main pharmaceuticals index slid by 2 percent as all 20 listed drugmakers fell in price. Industry giant Sun Pharmaceutical Industries sank 3 percent, despite Indian drugmakers mainly producing generics, which are not targeted by new tariffs. Australia’s largest biotechnology company, CSL, plunged to a six-year low, closing 1.9 percent below the previous day. Despite the initial shock reflected in share prices, experts said Indian companies should not suffer too much from the tariffs, as some that supply products to the US are already based there and will therefore be exempt. Namit Joshi, chairman of the Pharmaceutical Export Promotion Council of India, told CNN that the tariffs are “unlikely to have an immediate impact on Indian exports”. “The bulk of our contribution lies in simple generics, and most large Indian companies already operate US manufacturing or repackaging units and are exploring further acquisitions,” Joshi said. However, the uncertainty over whether the tariffs might be extended to generic medicines too weighs heavily on the Indian industry at a time when the country is already grappling with 50 percent tariffs imposed on other sectors by Trump earlier in the year. These were, in part, due to India’s continued purchase of Russian oil, Trump said. Other foreign pharmaceutical companies will also get around tariffs by locating their operations in the US, some experts said. “The US market is the world’s largest destination for branded and speciality drugs,” Adam Butlin, a pre-doctoral research assistant in the Centre for Economic Performance at the London School of Economics, told Al Jazeera. “Over the medium term, firms may attempt to redirect exports to other regions to circumvent tariffs, while in the longer term, some foreign producers may consider relocating production to the US.” But that will not be easy. “Such moves are constrained by the high costs of rebuilding supply chains and the policy uncertainty that discourages large-scale, long-term investment,” Butlin said. In the meantime, that unpredictability means that “exporting economies with significant exposure, such as India, Switzerland, and parts of the EU, could see a significant fall in competitiveness”. The pharmaceutical industry group, Pharmaceutical Research and Manufacturers of America (PhRMA), warned that tariffs could affect investment in US pharmaceuticals. “PhRMA companies continue to announce hundreds of billions in new US investments thanks to President Trump’s pro-growth tax and regulatory policies,” Alex Schriver, senior vice president at PhRMA, said in a statement. “Tariffs risk those plans because every dollar spent on tariffs is a dollar that cannot be invested in American manufacturing or the development of future treatments and cures.” Furthermore, he said, medicines are usually spared from tariffs to avoid higher costs and shortages. Butlin said the impact of this policy on the US pharmaceutical industry is “ambiguous”. “On one hand, domestic manufacturers may benefit from a reduction in foreign competition and new incentives to reshore parts of the supply chain. However, consumers, hospitals, and insurers will face higher drug prices and possible shortages, especially in areas where no domestic substitutes exist.” In the long run, the new policy may encourage more local investment in making medicines. But it could also raise healthcare costs and slow down innovation, if companies cut back on research to make up for the extra expenses, Butlin added. In another post on Truth Social, Trump wrote that the US will also impose a 50 percent tariff on all kitchen cabinets, toilet vanities and “associated products” and a 30 percent tariff on upholstered furniture. Upholstered furniture refers to any furniture that includes padding, springs and fabric or leather coverings. In a separate post, he announced a 25 percent tariff on “Heavy (Big!) Trucks” imported by the US from other countries. These tariffs will also go into effect on October 1. Trump did not specify his reasons for increasing tariffs on branded pharmaceutical products. However, he wrote that the tariffs on kitchen and toilet materials, as well as furniture, were down to “the large scale ‘FLOODING’ of these products into the United States by other outside Countries”. Trump called this “flooding” unfair. “We must protect, for National Security and other reasons, our Manufacturing process,” he wrote. Follow Al Jazeera English:...

The US largely imports pharmaceutical products from India and European countries, including Ireland, Switzerland and Germany. By Sarah Shamim Share Save United States President Donald Trump said on Thursday that he will impose a 100 percent import tax on pharmaceutical drugs. He also announced new tariffs on other products. Here’s what we know, and what it all means. In a post on his Truth Social platform, Trump wrote that starting on October 1, the US will impose a 100 percent tariff on any branded or patented pharmaceutical product. The 100 percent tariff means prices of imported pharmaceutical products will double for US importers and consumers. However, Trump said an exception would be made for any company which “IS BUILDING their Pharmaceutical Manufacturing Plant in America”. He explained that “is building” refers to “‘breaking ground’ and/or ‘under construction'”. Trump did not specify whether the new tariffs he announced would be applied on top of the national tariffs he has previously imposed on various US trading partners. Pharmaceutical products, including packaged medicaments; vaccines, toxins and cultures; and hormones, made up about 5.6 percent of total US imports in 2023, worth about $158bn, according to the Observatory of Economic Complexity (OEC). During that year, the US imported $86.4bn worth of packaged medicaments. About 14.2 percent, or $12.3bn worth, of packaged medicaments came from Ireland; 14 percent, or $12.1bn worth, came from Switzerland; 13.4 percent ($11.6bn) from Germany; and 10.6 percent, or $9.2bn worth, came from India. Other countries from which the US imported these products include Italy, Denmark and the United Kingdom. In 2023, the US imported $65.1bn worth of vaccines, blood, antisera, toxins and cultures. Out of this, 23.2 percent, or $15.1bn worth, came from Ireland and 20.9 percent, or $13.6bn worth, from Germany. Pharmaceutical companies across Asia and Europe saw a drop in their share prices following Trump’s announcement. Swiss companies Lonza, Novartis and Roche were down about 1.2 percent in early trading on Friday. Shares in German drugmakers Merck and Bayer also fell by 1.1 percent and 1.5 percent, respectively. Japan’s Sumitomo Pharma closed 3.5 percent lower, while Otsuka Holdings fell 2.9 percent and Daiichi Sankyo dropped 2 percent. Not all pharma groups took a hit, however. Takeda Pharmaceutical edged down just 0.1 percent, while Shionogi, instead of falling, rose 1 percent. Meanwhile, in India, the main pharmaceuticals index slid by 2 percent as all 20 listed drugmakers fell in price. Industry giant Sun Pharmaceutical Industries sank 3 percent, despite Indian drugmakers mainly producing generics, which are not targeted by new tariffs. Australia’s largest biotechnology company, CSL, plunged to a six-year low, closing 1.9 percent below the previous day. Despite the initial shock reflected in share prices, experts said Indian companies should not suffer too much from the tariffs, as some that supply products to the US are already based there and will therefore be exempt. Namit Joshi, chairman of the Pharmaceutical Export Promotion Council of India, told CNN that the tariffs are “unlikely to have an immediate impact on Indian exports”. “The bulk of our contribution lies in simple generics, and most large Indian companies already operate US manufacturing or repackaging units and are exploring further acquisitions,” Joshi said. However, the uncertainty over whether the tariffs might be extended to generic medicines too weighs heavily on the Indian industry at a time when the country is already grappling with 50 percent tariffs imposed on other sectors by Trump earlier in the year. These were, in part, due to India’s continued purchase of Russian oil, Trump said. Other foreign pharmaceutical companies will also get around tariffs by locating their operations in the US, some experts said. “The US market is the world’s largest destination for branded and speciality drugs,” Adam Butlin, a pre-doctoral research assistant in the Centre for Economic Performance at the London School of Economics, told Al Jazeera. “Over the medium term, firms may attempt to redirect exports to other regions to circumvent tariffs, while in the longer term, some foreign producers may consider relocating production to the US.” But that will not be easy. “Such moves are constrained by the high costs of rebuilding supply chains and the policy uncertainty that discourages large-scale, long-term investment,” Butlin said. In the meantime, that unpredictability means that “exporting economies with significant exposure, such as India, Switzerland, and parts of the EU, could see a significant fall in competitiveness”. The pharmaceutical industry group, Pharmaceutical Research and Manufacturers of America (PhRMA), warned that tariffs could affect investment in US pharmaceuticals. “PhRMA companies continue to announce hundreds of billions in new US investments thanks to President Trump’s pro-growth tax and regulatory policies,” Alex Schriver, senior vice president at PhRMA, said in a statement. “Tariffs risk those plans because every dollar spent on tariffs is a dollar that cannot be invested in American manufacturing or the development of future treatments and cures.” Furthermore, he said, medicines are usually spared from tariffs to avoid higher costs and shortages. Butlin said the impact of this policy on the US pharmaceutical industry is “ambiguous”. “On one hand, domestic manufacturers may benefit from a reduction in foreign competition and new incentives to reshore parts of the supply chain. However, consumers, hospitals, and insurers will face higher drug prices and possible shortages, especially in areas where no domestic substitutes exist.” In the long run, the new policy may encourage more local investment in making medicines. But it could also raise healthcare costs and slow down innovation, if companies cut back on research to make up for the extra expenses, Butlin added. In another post on Truth Social, Trump wrote that the US will also impose a 50 percent tariff on all kitchen cabinets, toilet vanities and “associated products” and a 30 percent tariff on upholstered furniture. Upholstered furniture refers to any furniture that includes padding, springs and fabric or leather coverings. In a separate post, he announced a 25 percent tariff on “Heavy (Big!) Trucks” imported by the US from other countries. These tariffs will also go into effect on October 1. Trump did not specify his reasons for increasing tariffs on branded pharmaceutical products. However, he wrote that the tariffs on kitchen and toilet materials, as well as furniture, were down to “the large scale ‘FLOODING’ of these products into the United States by other outside Countries”. Trump called this “flooding” unfair. “We must protect, for National Security and other reasons, our Manufacturing process,” he wrote. Follow Al Jazeera English:...

The celebrations were wild. As Pedro Neto's 93rd-minute stunner completed a defiant Chelsea fightback at Fulham, there was no doubt about the importance of the strike. Chelsea leapfrogged rivals Aston Villa and Nottingham Forest to return to the Premier League top five, a spot which would earn the club qualification for the Champions League next season. And, after weeks of negativity around Chelsea's form and hostility from sections of supporters towards head coach Enzo Maresca, the players and fans celebrated as one - with the scenes carrying on long after the final whistle. Chelsea's first away league win of the year was sparked by the introduction of 18-year-old academy product Tyrique George, with his 83rd-minute equaliser the prelude to a dramatic finale. And it all came just when Chelsea's top-five challenge was in danger of fizzling out. Had Chelsea drawn, we would be talking about a club without a win in nine away matches, seventh in the table with goalkeeper Robert Sanchez's struggling and several goalless forwards. But, instead, Maresca was able to speak in bullish fashion about his side's season. "Chelsea in the last two years have never been in the Champions League spot and this season we spent the whole season there," he said. "Today doesn't change my view, it is already a good season and can become very good if we finish in the Champions League spot. "But for sure today was an important win because it is a derby and can give us a chance - it was probably also the most difficult win - because our rivals all played yesterday so it is was must-win." After celebrating on the touchline, Maresca went down the tunnel rather than join his players and coaching staff in soaking in an important victory with the 3,000-strong away support. He will know Chelsea's first-half performance left a lot to be desired at Craven Cottage, with the late goal showing the mission to return to the Champions League after two seasons away is still on a knife edge. There are still some causes for concern at Chelsea after the comeback win, with struggling forward Christopher Nkunku left out due to a "technical decision". In addition, Maresca said that defender Malo Gusto's muscular injury is "not a good one" and the Frenchman joins defender Wesley Fofana and striker Marc Guiu on the injured list, with winger Mykhailo Mudryk provisionally suspended following a failed drugs test. After the match, Maresca said his decision not to celebrate with the away end was more about giving his players time in the spotlight. He said: "I was very happy because it is a nice feeling to win the game at the end but I think it was a moment for the players because they deserve to celebrate with the fans. "That's the reason I left the pitch immediately. And then when we scored the second one, I celebrated and this was the reason they give me the yellow card, but it was a nice moment between the players and the fans to share that moment. I said many times, the players need to feel that support." There remains concern about the 16-game goal drought of Cole Palmer and Chelsea's general lack of production from their forward line. Jadon Sancho's strike against Ipswich last week, ending a run of 21 games without scoring, was the first by a Chelsea forward in the league since 25 February. Striker Nicolas Jackson has not found the net in 13 matches, while match-winner Neto's goal was his first in eight matches. Tyrique George was promoted from the academy team to the first team on 19 December in a touching moment filmed by the club's channels. He and defender Josh Acheampong were both given permanent first-team lockers after signing new deals in 2024, and most of their opportunities for game time have come in the Conference League. George, who has been with Chelsea since the age of eight, made 10 Conference League appearances, scoring his first goal for the club away at Legia Warsaw in the last round. He is the fifth youngest Premier League scorer for Chelsea and youngest since Callum Hudson-Odoi against Burnley in 2020. "I think Tyrique, when he scored, it was a nice moment but also gave an extra energy to the players to try to win the game in the last minute," said Maresca. "I'm very happy for Tyrique, Ty and Josh both from the academy are good talents, they have to work hard."